Skip to main content
. 2018 Feb 1;15(4):5280–5284. doi: 10.3892/ol.2018.7923

Table I.

Cell cycle distribution in each group following treatment for 48 h.

Treatment group, %

Cell cycle phase A, Nimotuzumab B, Cisplatin C, Sequential treatment D, Simultaneous treatment E, Untreated control
G0/G1 61.72±1.68 66.40±2.31 72.23±2.07 62.28±1.68 58.25±1.07
S 12.32±1.32 8.78±0.91 5.87±0.78 11.01±1.37 15.35±0.54
G2-M 24.91±0.62 24.48±2.80 24.16±1.86 26.71±1.31 26.40±0.53

Data are presented as the mean ± standard deviation.